Latest Breaking News On - Eyepoint pharmaceuticals trading - Page 1 : comparemela.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $38 00 by Analysts at Robert W Baird

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $38 00 by Analysts at Robert W Baird
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdChina universal asset management coInvestment advisersJpmorgan chase coAnalyst recommendations for eyepoint pharmaceuticalsEyepoint pharmaceuticals incEyepoint pharmaceuticals tradingTower research capitalEyepoint pharmaceuticals company profileSecurities exchange commissionHedge funds weigh in on eyepoint pharmaceuticalsSherbrooke park advisersNews ratings for eyepoint pharmaceuticals dailyToth financial advisory corpEyepoint pharmaceuticalsGet free report

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38 00

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdTower research capitalEyepoint pharmaceuticals tradingEyepoint pharmaceuticals incAnalyst recommendations for eyepoint pharmaceuticalsJpmorgan chase coInstitutional trading of eyepoint pharmaceuticalsEyepoint pharmaceuticalsToth financial advisory corpNews ratings for eyepoint pharmaceuticals dailySherbrooke park advisersChina universal asset management coInvestment advisersGet free reportCapital one financialPoint pharmaceuticals

Insider Selling: EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock

Insider Selling: EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Darioa paggiarinoNews ratings for eyepoint pharmaceuticals dailyLazard asset managementJpmorgan chase coQuarter for eyepoint pharmaceuticalsEyepoint pharmaceuticals incInstitutional trading of eyepoint pharmaceuticalsChina universal asset management coInvestment advisersToth financial advisory corpTower research capitalEyepoint pharmaceuticalsEyepoint pharmaceuticals tradingGet free reportPoint pharmaceuticalsOne financial

EyePoint Pharmaceuticals, Inc (NASDAQ:EYPT) Major Shareholder Sells $2,036,273 60 in Stock

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) major shareholder Ew Healthcare Partners, L.P. sold 139,280 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $14.62, for a total transaction of $2,036,273.60. Following the sale, the insider now owns 3,883,760 shares […]

United kingdomUnited statesTower research capitalSchonfeld strategic advisorsCubist systematic strategiesEyepoint pharmaceuticals tradingEyepoint pharmaceuticals incBarclays plcSecurities exchange commissionEyepoint pharmaceuticals company profileEyepoint pharmaceuticalsNews ratings for eyepoint pharmaceuticals dailyLazard asset managementGet free reportExchange commissionHealthcare partners

EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to Hold at StockNews com

StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) from a sell rating to a hold rating in a report published on Friday. A number of other research firms also recently weighed in on EYPT. Chardan Capital reissued a buy rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a […]

United statesUnited kingdomRobertw bairdEyepoint pharmaceuticals tradingVontobel holding ltdEyepoint pharmaceuticals company profileSchonfeld strategic advisorsNews ratings for eyepoint pharmaceuticals dailyTower research capitalCubist systematic strategiesHedge funds weigh in on eyepoint pharmaceuticalsEyepoint pharmaceuticals incBarclays plcEyepoint pharmaceuticalsFree reportModerate buy